Spectrumedics

What Spectrumedics does

Spectrumedics (谱创医疗科技（上海）有限公司) is a Shanghai-based medical device company founded in 2019 that develops proprietary cardiovascular interventional products, with its core offering being the Sonico-CX® coronary intravascular shockwave (IVL) treatment system. The Sonico-CX system consists of a single-use rapid-exchange balloon catheter and a treatment console that delivers 360° circumferential acoustic pressure wave pulses to fracture calcified deposits in coronary arteries; it supports up to 120 pulses per catheter, offers seven diameter options (2.50–4.00mm), and features a reduced crossing profile for access to heavily calcified lesions. The system received NMPA approval in 2024 (registration numbers 国械注准20243010464 and 国械注准20243010505) and is supported by the COCALP pivotal trial published in MedComm (IF=10.7) showing a 97.4% procedural success rate across 266 patients in 12 institutions. The company holds 30+ global patents and maintains GMP, ISO 13485, and MDSAP certifications.

Spectrumedics sells its hardware through direct enterprise field sales targeting tertiary and quaternary cardiovascular hospitals in China, supported by an academic-led go-to-market strategy built on key opinion leader (KOL) relationships with leading interventional cardiologists such as Academician Ge Junbo at Zhongshan Hospital (Fudan University). Revenue is generated primarily through medical device sales, supplemented by clinical services and research collaborations from international partnerships. The company has secured ARCSA registration in Ecuador and is conducting its first overseas clinical study with the Sarawak Heart Centre in Malaysia as part of its Belt and Road international expansion, while preparing for US, EU, and Brazil market entry via its Singapore R&D center and overseas market hub. Spectrumedics is privately held and has completed four funding rounds (Pre-A 2020, Series A 2022, Series A+ 2024) with undisclosed amounts and investors, and is led by Founder and CEO Dr. Peng Huiqun and Co-founder and Chief Engineer Al Ray Tabiliran.

Name

Spectrumedics

Legal name

谱创医疗科技（上海）有限公司

Website

https://spectrumedics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Spectrumedics (谱创医疗) is a Shanghai-based medical device company founded in 2019 that develops and commercializes the Sonico-CX® coronary intravascular shockwave (IVL) catheter system for treating calcified coronary lesions, selling directly to tertiary cardiovascular hospitals in China and expanding internationally.

Ownership category

akta.pro rank

Product category

Interventional Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

akta.pro secondary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

Keywords

• Intravascular lithotripsy devices
• Coronary intervention catheters
• Medical device manufacturing
• Cardiovascular medical devices
• Shockwave therapy systems

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Medical Device Sales: Sale of proprietary intravascular shockwave catheter systems and treatment devices to hospital customers for cardiovascular interventional procedures.
2. Clinical Services & Research Collaborations: Revenue generated through international clinical trial collaborations with overseas medical institutions (e.g., Sarawak Heart Centre, Malaysia), including技术服务 and clinical study support.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Spectrumedics develops, manufactures, and sells the Sonico-CX coronary intravascular shockwave (IVL) treatment system — consisting of a single-use shockwave balloon catheter and a treatment console — used by interventional cardiologists to fracture calcified deposits in coronary arteries during PCI procedures. The company is the only domestically developed and patented IVL system in China, selling primarily through direct enterprise sales to tertiary cardiovascular hospitals.

Product overview

Spectrumedics offers a unified coronary intravascular shock wave treatment system (Sonico-CX®) consisting of two core components: a disposable shock wave catheter and the treatment equipment console. The system delivers 360° circumferential shock wave pulses via a rapid-exchange balloon catheter to fracture calcified deposits in coronary arteries. The catheter offers 7 size options (2.50-4.00mm) with up to 120 pulses per device. As the only domestically developed and patented coronary shock wave treatment product in China, the system has received NMPA approval and international recognition including ARCSA registration in Ecuador and publication of clinical trial results in the MedComm journal (IF=10.7).

Differentiator

Problem solved

Functional benefit

Brands

• Sonico-CX®: Coronary intravascular shock wave treatment system consisting of disposable coronary intravascular shock wave catheter and vascular intravascular shock wave treatment equipment for treating coronary artery stenotic calcified lesions.

Products and services

• Sonico-CX® Disposable Coronary Intravascular Shock Wave Catheter A single-use balloon catheter that delivers 360° circumferential shockwave pulses (up to 120 pulses per catheter) to fracture calcified deposits in coronary arteries. Features rapid exchange (RX) design, seven diameter sizes (2.50–4.00mm), and a reduced crossing profile for deliverability in narrow and heavily calcified vessels. Sold to hospitals for use in PCI procedures; NMPA registration number 国械注准20243010464.
• Intravascular Shock Wave Treatment Equipment (Console) The treatment console that delivers pulsed electrical energy to the Sonico-CX shockwave catheter, generating 360° circumferential acoustic pressure waves to fracture calcium deposits while avoiding damage to the vascular intima. Sold to hospitals as the capital equipment paired with the disposable catheter; NMPA registration number 国械注准20243010505.
• Sonico-CX® Coronary Intravascular Shock Wave Treatment System The complete Sonico-CX treatment system combining the disposable shockwave catheter and the treatment equipment console, indicated for treating coronary artery stenotic calcified lesions during PCI. The only domestically developed and patented coronary intravascular shockwave treatment product in China that has broken through foreign technical bottlenecks. Achieved 97.4% procedural success rate and 76.8% OCT-assessed calcium fracture rate in the COCALP pivotal trial.

Quantifiable outcome

• 97.4% surgical success rate in COCALP trial (259/266 patients), significantly exceeding预设 performance target
• +5 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Pusat Jantung Sarawak (沙捞越心脏中心), MalaysiacoreStrategic or Co-development Partner · 1 January 2024Spectrumedics signed a cooperation memorandum with Malaysia's Sarawak Heart Centre to conduct a clinical study on the safety and efficacy of the SONICO-CX® intravascular shockwave lithotripsy system. This prospective, single-group clinical trial enrolled 12 patients, with OCT evaluation showing calcium lesions with visible fractures post-treatment. This is the company's first overseas clinical collaboration and a key stepping stone for international expansion under the Belt and Road initiative.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Shockwave Medical (Johnson & Johnson MedTech): The originator and global market leader in intravascular lithotripsy (IVL), including the coronary Shockwave M5+ and peripheral S4 systems. Acquired by Johnson & Johnson in 2024, it is the most direct competitor to Sonico-CX across indications, customers, and technology.
• OrbusNeich Medical: Hong Kong-headquartered developer of coronary balloons (including scoring/cutting), stents, and ablation catheters. Comparable as a regional peer in coronary interventional catheter technology targeting overlapping hospital customers in Asia.

Broad incumbents

• Boston Scientific: Global interventional cardiology incumbent with cutting and scoring balloons (Wolverine), imaging, and a peripheral IVL franchise (Javelin via Bolt acquisition). Comparable as a broad incumbent whose portfolio competes with and may eventually bundle against Sonico-CX.
• Abbott Vascular: Global leader in coronary intervention (XIENCE stents, Dragonfly OCT, and Diamondback atherectomy via CSI). Comparable as a broad incumbent offering multiple tools for calcified-PCI workflows that bracket IVL's positioning.
• Lepu Medical Technology: One of China's largest cardiovascular interventional device manufacturers spanning stents, balloon catheters, and structural heart products. Comparable as a domestic incumbent sharing Chinese interventional cardiology hospital customers and competing for procurement share.
• MicroPort Scientific Corporation: A leading Chinese interventional cardiology platform (coronary stents, balloon catheters, and increasingly structural heart). Comparable as a domestic competitor with overlapping hospital customers and similar regulatory pathway, though with a far broader product portfolio.
• JW Medical Systems: A major Chinese interventional cardiology business focused on coronary stents and balloon catheters. Comparable as a domestic device platform competing for hospital shelf space and KOL endorsements with Sonico-CX.
• Cardiovascular Systems / CSI (Abbott): Acquired by Abbott in 2023, CSI commercializes the Diamondback 360 orbital atherectomy system for severely calcified lesions, a complementary but distinct calcium-modification technology to IVL. Highly comparable from a use-case and customer perspective.

Emerging players

• FastWave Medical: An early-stage US-based developer of IVL and adjacent calcium-modification devices targeting coronary and peripheral indications. Comparable as a focused IVL entrant competing in the same clinical use cases that Spectrumedics targets.
• Peijia Medical: A Chinese innovator in interventional cardiology and structural heart devices (notably TAVR). Comparable as a fellow domestically-developed, KOL-led cardiovascular device company competing for the same pool of KOL endorsements and hospital procurement.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spectrumedics